DG DISPATCH - APA: Paroxetine Safer than Mirtazapine for Car Driving Performance
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




DG DISPATCH - APA: Paroxetine Safer than Mirtazapine for Car Driving Performance

By Lara Pullen
Special to DG News

CHICAGO, IL -- May 18, 2000 -- The antidepressant, paroxetine (20 mg/day), has no psychomotor or behavioral toxicity and has no negative impact on brake reaction time in a driving skills test.

In contrast, mirtazapine (15-30 mg/day), another antidepressant, significantly was shown to impair driving performance on all measures.

At the 2000 Annual Meeting of the American Psychiatric Association, Fran Ridout, MD, of the University of Surrey, England, presented the results of a double blind, balanced, four-way crossover study designed to assess the effects of paroxetine and mirtazapine on driving skills.

Twelve healthy volunteers received each medication protocol for five days. The brake reaction time (BRT) and self-assessed ratings of sedation (LARS) were administered at 14:00 on day 0 (baseline) and at 10:30 and 14:30 on days two and five.A psychometric test battery was administered at 7:00 on days 1, 2, 3, 4, and 5.

Paroxetine had no significant effect on BRT or co-administered LARS compared to placebo. Mirtazapine significantly reduced reaction time (CRT) scores compared to placebo. All treatments significantly impaired morning LARS scores relative to placebo.

Subjective ratings of sleep quality (LSEQ) were significantly improved by mirtazapine and significantly impaired by paroxetine. Thus, paroxetine seems to be suitable for use in an ambulant population. It is inadvisable, however, to use mirtazapine to treat ambulant depressed patients.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities